cyrilzakka/clinical-trials huggingface dataset:
Developing Lung Cancer Screening in Hodgkin Lymphoma Survivors: a Qualitative Study

To explore the topic of lung cancer screening following treatment for Hodgkin lymphoma from the perspective of survivors

Explore survivors' attitudes towards lung cancer and lung cancer screening Explore survivors' understanding of cancer screening as a concept and the benefits of screening and early detection Explore survivors' level of awareness of and attitudes towards their lung cancer risk Explore survivors' views on the barriers and motivating factors that would impact their decision to attend a lung cancer screening test

Eligibility Criteria:
Inclusion Criteria:

* Details held in the ADAPT database at The Christie NHS Foundation trust
* Responded to most recent ADAPT study questionnaire (April - August 2019)
* Aged 18-80
* Previously treated for Hodgkin lymphoma without evidence of relapse for at least 5 years
* Able to provide informed consent
* Treated with radiotherapy (with lung tissue in the radiotherapy field) and/or alkylating agent containing chemotherapy.

Exclusion Criteria:

* Previous or current diagnosis of lung cancer
* Stated within 2019 health questionnaire that they did not wish to be contacted
* Have participated in lung cancer screening through the Manchester Lung Health Checks
Effectiveness of Creatine Supplementation and Exercise on Muscle and Bone

As we age, we experience a reduction in muscle and bone which inevitably decreases strength and the ability to perform tasks of daily living such as gardening, carrying groceries, and climbing stairs. Health costs associated with aging muscle and bone loss are in the billions of dollars. With the projected increase in life expectancy, the incidence of muscle and bone loss will rise and further drain the healthcare system, with greater need for hospitalization, treatment, and rehabilitation. Without effective strategies to counteract aging muscle and bone loss, we may face a healthcare crisis in the future. Creatine, a compound found in red meat and seafood, increases creatine phosphate stores in muscle, providing increased energy during high-intensity exercise. Short-term (i.e. 3-4 months) resistance-exercise and supplementation with creatine, have been shown to have a favorable effect on properties of aging muscle and bone. However, the longer-term (i.e. 1 year) effects of these interventions are unknown. Therefore, the purpose of this innovative research is to determine the longer-term effects of resistance-exercise and creatine supplementation (0.1g•kg-1) in older adults. The primary dependent variables to be assessed will include muscle hypertrophy, bone mineral and bone geometry, strength, and urinary and blood indicators of liver and kidney function. This innovative, multidisciplinary research will help contribute to the successful pursuit of prolonged independent living by improving aging musculoskeletal health for older Saskatchewan adults. Saskatchewan provides a relevant setting for this research, given the higher percentage of older adults (15%), compared to the national average (12%).

We hypothesize that creatine supplementation will increase muscle mass, strength, and bone mineral density more than placebo.


Eligibility Criteria:
Inclusion Criteria:

* greater than or equal to 50 years of age
* males or postmenopausal females
* not currently participating in resistance training

Exclusion Criteria:

* pre-existing kidney abnormalities
* previous fragility fractures
* history of taking medications that affect bone mineral density in the past year including bisphosphonates, parathyroid hormone, calcitonin, hormone replacement therapy, or corticosteroids (i.e. within the past year)
* suffer from severe osteoarthritis
* have taken creatine supplementation within the past 6 months
TElemedicine to Replace Face-to-face Physician Consultation in Patients With HyperTension : a Pilot Randomized-controlled Trial

The investigators has developed a blood pressure telemonitoring system. It is hypothesized that, when optimal control of BP is confirmed on the telemonitoring system, the index physician's consultation can be safely deferred, and medications can still be prescribed without such face-to-face consultation. Despite potentially resource-saving for doctors and time-saving for patients, the feasibility and patients' acceptability of the use of the telemonitoring system to replace face-to-face physician consultation remains unclear.

For primary outcome, the investigators hypothesize that this telemonitoring system will be feasible and acceptable to patients and can replace physicians' face-to-face consultations. For secondary outcomes, the investigators hypothesize that patients receiving care through telemonitoring have non-inferior BP control when compared with patients receiving usual care. Furthermore, the patients receiving telemonitoring may also have enhanced self-efficacy and compliance to drugs and lifestyle interventions


Eligibility Criteria:
Inclusion Criteria:

* have a diagnosis of essential hypertension (HT) and are currently taking antihypertensive agents
* have good control of clinic BP as confirmed on ambulatory blood pressure monitoring (ABPM) (daytime BP ≤135/85mmHg)
* can read basic Chinese (as the content of the app in Chinese)
* have a home BP monitor (HBPM)
* used any mobile app (not HT-related) in the previous 1 year

Exclusion Criteria:

* an inability to give informed consent
* unwillingness to conduct HBPM or repeated ABPM
* current use of any other HT app for BP monitoring
* relative contraindications to ABPM (diagnosed atrial fibrillation, occupational drivers or patients with bleeding tendencies)
* severe mental illness, including those diagnosed with schizophrenia, dementia or as being actively suicidal, because these patients may have diminished ability to use the HT app;
* a diagnosis of other chronic disease(s) that need regular physical assessments and doctors' consultations (e.g. diabetes and asthma that are being treated, but patients with hypertension and hyperlipidaemia will remain eligible)
* diagnosed active cancer,
Micro-RNA Expression Profiles in High Risk Prostate Cancer

The purpose of this study is to determine whether specific Micro-RNA expression profiles are related to Prostate cancer outcome.


Eligibility Criteria:
Inclusion Criteria:

Patients with clinically localised high risk prostate cancer (cT\>2, bx GS \>7, PSA \>20 ng/ml) scheduled for radical prostatectomy.

Exclusion Criteria:

Non high risk prostate cancer
Naloxone Treatment in Skåne County - Effect on Drug-related Mortality and Overdose-related Complications

Death in overdose is the single most common cause of death in people using heroin. In Sweden, the number of drug-related overdose deaths has increased gradually since the early 1990s. The purpose of the study is to investigate the effects of a Naloxone distribution program in Skåne County. The primary issue is whether the project had an effect on overdose mortality and overdose related injuries.


Eligibility Criteria:
Inclusion Criteria:

* subjects treated at the Addiction centres of Skåne County
* signed informed consent

Exclusion Criteria:

* subjects unable to understand study information due to psychiatric co-morbidity or severe language difficulties
Electrotherapy in the Management of Myofascial Syndrome

Myofascial syndrome is defined as "musculoskeletal pain characterized by local and referred pain perceived to be deep and constant, and by the presence of myofascial trigger points in any part of the body" Post-breast surgery myofascial syndrome affects up to 44.7% of operated women, mainly on the muscles of the greater shoulder girdle. The repercussions are significant, functional, somatic, psychological and socio-professional affecting the quality of life. The treatments offered may or may not be medicinal. Transcutaneous electrical nerve stimulation (TENS) is a therapy that uses low voltage electrical current to provide pain relief. A TENS unit consists of a battery-powered device that delivers electrical impulses through electrodes placed on the surface of your skin. The electrodes are placed at or near nerves where the pain is located or at trigger points.


Eligibility Criteria:
Inclusion Criteria:

* Male or female who had first breast cancer surgery, regardless of the type of surgery
* Age ≥ 18 years
* Patients with refractory pain with myofascial syndrome, with a numerical scale ≥ 4
* Topical treatment for refractory pain completed more than 30 days ago
* Healthy, non-irritated skin on painful areas to treat
* Patient with a third party who can attend visits M0 and M2.5
* Obtaining the signed written consent of the patient
* Major patient affiliated to a social security scheme

Exclusion Criteria:

* Patient who has used TENS before on the muscles affected by the myofascial syndrome
* Post-surgery management of the affected area by a physiotherapist
* Person with venous thrombosis
* Contraindications specific to the treatments studied
Acne Remission Maintenance by Weekend Systemic Isotretinoin

The goal of this study is to learn if isotretinoin oral tablets as a weekend regimen are safe and effective to maintain freedom from acne lesions in young adults who have completed a full course of isotretinoin on daily basis and achieved total control of the acne activity.

Three groups of adult acne patients will be given a full course of isotretinoin with a cumulative dose of 120-150 mg/Kg weight in the 1st two groups, and till lesional clearance in the 3rd group with an additional month of maintenance. Afterwards, the 1st group will use adapalene gel every other day for maintenance, the 2nd and 3rd groups will use weekend oral isotretinoin. Patients will be followed for a year for reappearance of acne lesions, and safety of maintenance regimens. Patients opinion will be also sought.

Eligibility Criteria:
Inclusion Criteria:

* Adult patients (≥ 18 years) with moderate to severe facial acne, as per the Investigator Global Assessment (IGA) scale

Exclusion Criteria:

* patients on systemic acne medications in the past 3 months or topicals in the last month, pregnant or breastfeeding females, those with evidence of endocrine disturbances or using medications for comorbidities
External Pancreatic Stent in Pancreaticojejunostomy

Pancreatic fistula is one of the most serious complication after pancreatoduodenectomy. To reduce pancreatic fistula, many authors recommend pancreatic stent in pancreatojejunostomy. The purpose of this study is to determine which is the best method in preventing pancreatic fistula and to investigate its long term clinical outcomes.

The role of external pancreatic duct drainage in managing patients with a soft pancreas is particularly important, as these patients are at a heightened risk of developing postoperative complications. By providing an external route for pancreatic secretions, external pancreatic duct drainage may help to reduce the enzymatic activity at the anastomosis site and promote better healing.

In addition to reducing the incidence of post operative pancreatic fistula, external pancreatic duct drainage may have other potential benefits, such as decreasing the length of hospital stay, reducing the need for additional interventions, and improving overall patient quality of life. However, these potential benefits must be weighed against the risks and drawbacks of external pancreatic duct drainage, including the potential for stent-related complications and the need for an additional procedure to remove the stent.

•After being informed about the study and potential risks, all patients giving written consent. Patients who meet the eligibility requirements will be randomized in double blind manner (participant and investigator) in a 1:1 ratio to external pancreatic drainage group and no external pancreatic drainage group.

Eligibility Criteria:
Inclusion Criteria:

* Patients undergoing pancreaticoduodenectomy (Whipple procedure) for various indications (e.g., pancreatic cancer, ampullary cancer, etc.).
* Patients with a confirmed soft pancreas texture, as determined intraoperatively by the surgeon.

Exclusion Criteria:

* Patients with a hard or fibrotic pancreas, as determined intraoperatively by the surgeon.
* Patients with severe uncontrolled comorbidities (e.g., uncontrolled diabetes, severe cardiovascular disease, renal failure).
* Pregnancy or lactation.
Pilot-Study DCPT for PTSD in Adolescents and Young Adults

The aim of this pilot study is to evaluate the developmentally adapted cognitive processing therapy (D-CPT)in adolescents suffering from childhood abuse(CA)or physical abuse (PA) related PTSD. D-CPT's feasibility and efficacy will be examined in 20 adolescents suffering from CA or PA-related PTSD in a multicenter study (3 sites).Patients will be assessed prior to (t0), post (t1) and 6 weeks after treatment (t2). Assessments include Clinician Administered PTSD Scale (CAPS), UCLA PTSD Index (UCLA), Beck Depression Inventory (BDI), Adolescent Dissociative Experiences Scale (A-DES), and Borderline Symptom List (BSL-23).

The aim of this pilot study is to evaluate the developmentally adapted cognitive processing therapy (D-CPT)in adolescents suffering from childhood sexual abuse (CA) or childhood physical abuse (PA) related PTSD. D-CPT's feasibility and efficacy will be examined in 20 adolescents suffering from CA or PA-related PTSD in a multicenter study in Berlin, Frankfurt and Ingolstadt in Germany (3 sites).Patients will be assessed prior to (t0), post (t1) and 6 weeks after treatment (t2). Assessments include Clinician Administered PTSD Scale (CAPS), UCLA PTSD Index (UCLA), Beck Depression Inventory (BDI), Adolescent Dissociative Experiences Scale (A-DES), and Borderline Symptom List (BSL-23).

Eligibility Criteria:
Inclusion Criteria:

* PTSD after CSA and/or CPA beyond the age of three (confirmed by a structured clinical interview, CAPS-CA, German Version IBS-KJ)
* PTSD must be the primary diagnosis (most severe disorder according to SCID)
* age 14 - 21 years
* living in safe conditions
* informed consent from parents/legal guardians (if under 18) and participant

Exclusion Criteria:

* current psychotic
* substance related or organic mental disorder
* acute suicidality, severe medical conditions
* mental retardation
* insufficient knowledge of German language.
Lumax DX / Linox DX Evaluation

The objective of this study is to investigate the safety and efficacy of the Lumax DX / Linox DX system.

No hypothesis has been defined.


Eligibility Criteria:
Inclusion Criteria:

* Patient meets the indication for ICD therapy
* LVEF ≥ 30%
* Patient's compliance with protocol
* Signed patient informed consent form

Exclusion Criteria:

* Patient meets one contraindication for ICD therapy
* Permanent atrial tachyarrhythmia
* Age \< 18 years
* Cardiac surgery planned within the next 6 months
* Life expectancy of less than 6 months
* Limited contractual capability
* Participating in another clinical study of an investigational cardiac drug or device
Buccal Infiltration of Different Volumes of Articaine for Extraction.

This study compares the effectiveness of two different volumes of buccal infiltration of Articaine for the extraction of mandibular posterior teeth. One group receives buccal infiltration of 1.8 ml of 4% Articaine and the other group receives buccal infiltration of 3.6 ml of 4% Articaine.

The most widely and commonly used injection method for the extraction of mandibular posterior teeth is the inferior alveolar nerve block (IANB) technique. However, various complications like pain during injection, transient facial nerve paralysis, trismus, hematoma, and paresthesia are associated with the inferior alveolar nerve block technique.

Local infiltration technique has been proven as a safer and less painful anesthetic injection technique compared to IANB. Unfortunately, the dense nature of cortical bone in the mandibular posterior region hinders sufficient diffusion of anesthetic solution during infiltration. Thus, to achieve an adequate anesthesia for a painless dental extraction of mandibular posterior teeth by infiltration technique, a strong and effective local anesthetic agent having a deeper penetrating property should be used.

Articaine is one of the most widely used local anesthetic agents. It is more potent and has shown more success rate than Lidocaine and Mepivacaine in providing anesthesia in mandibular and maxillary posterior teeth by buccal infiltration diffusibility.

This study compares the effectiveness of two different volumes of buccal infiltration of Articaine for the extraction of mandibular posterior teeth.

Eligibility Criteria:
Inclusion Criteria:

* All healthy patients (ASA I) or patients with mild systemic disease with no functional limitations (ASA II)
* Patients aged ≥ 18 years of age.
* Patients requiring extraction of mandibular posterior teeth including grossly decayed tooth, grade I mobile tooth, root stumps and indicated for therapeutic reasons.
* Patients not allergic to the drugs or anesthetic agents used in the surgery.

Exclusion Criteria:

* Acute infection at the extraction site.
* Patients indicated for surgical extraction of teeth.
* Patients already taking medications affecting pain assessment.
* Pregnant patients.
Phase III PEG-Intron in HIV-infected Patients (Study P00738)

This is a randomized, double-blind, multicenter trial testing 2 doses of PEG-Intron, 1.0mcg/kg/week and 3.0mcg/kg/week in heavily treatment-experienced HIV-infected patients compared to placebo. The study will evaluate the efficacy and safety of PEG-Intron when added to stable optimized background antiretroviral therapy in this patient population.

This study will randomize 675 patients (225 in each of the 3 arms) to either: PEG-Intron 1mcg; 3mcg or Placebo, at 90 centers worldwide. Each center will enroll approximately 10 patients.

Study drug will be added to optimized background anti-retroviral therapy of patients whose HIV RNA is incompletely suppressed by their therapy (HIV RNA 400-50,000 copies/ML) after 2-6 months.

A single dose reduction of 50% will be allowed for toxicity. An Interim Analysis will be conducted when 50% of patients have completed 24 weeks of therapy. The study treatment phase will be 48 weeks with monthly visits for virologic virologic and safety monitoring. The primary endpoint is change in HIV RNA from baseline to week to assess efficacy. Durability of response will be assessed at 48 weeks.

Eligibility Criteria:
Inclusion Criteria:

* HIV positive
* History of virologic failure on at least 2 antiretroviral regimens including exposure to at least one NRTI, one NNRTI and one PI
* HIV RNA \>400-\<50,000 copies/mL
* Laboratory parameters: platelet count (75,000u/L, hemoglobin \>9gm/dl, absolute neutrophil count \>1,000/uL, SGOT/SGPT\<5xULN.

Exclusion Criteria:

* Current ribavirin therapy
* Subjects with a recent diagnosis or history of moderate or severe depression requiring ongoing psychiatric intervention
* Females of childbearing potential who are breastfeeding, who are pregnant, or not using adequate birth control measures
* Concomitant use of immunosuppressants or cytotoxic agents
* History of seizure disorder requiring use of anticonvulsants
The NO-ALS Study: a Trial of Nicotinamide/pterostilbene Supplement in ALS.

Amyotrophic lateral sclerosis (ALS) is a serious rapidly progressive disease of the nervous system. The average survival from the time of diagnosis is 3 years. Apart from Riluzole, there is no effective treatment. Care of advanced ALS will have a cost of 4-8 million NOK per year

Research i.a. from the investigators department has shown that increased activity in histone deacetylation enzymes (sirtuins) together with increased access to NAD can delay disease progression. Nicotinamide riboside (NR) can increase cells' access to NAD and Pterostilben will stimulate sirtuins.

The investigators want to study whether combination therapy with NR and Pterostilben can inhibit neurodegeneration in ALS and thereby delay disease development, increase survival and improve quality of life in ALS.

In the study, the investigators will use 2 different dosages on the active treatment and strength calculations show that 180 patients are needed to show a rather weak effect. Patients will be recruited in collaboration with hospitals in Helse Vest, AHUS, Drammen, OUS and St. Olavs hospital.


Eligibility Criteria:
Inclusion Criteria:

Arm 1 (newly diagnosed ALS patients)

* Have a clinical diagnosis of probable ALS according to the revised El Escorial criteria.
* MR of the brain and cervical spine cannot explain symptoms.
* Diagnosed with likely ALS within 6 months from enrolment and treated with Riluzole 50mg x 2
* Symptom onset no longer than 2 year prior to inclusion.
* ALS-FRC-R of 36 or more (not any item below 2).
* Age equal to or greater than 35 years at time of enrollment

Arm 2 (earlier diagnosed ALS patients)

* Have a clinical diagnosis of probable ALS according to the revised El Escorial criteria.
* MR of the brain and cervical spine cannot explain symptoms.
* Treated with Riluzole 50mg x 2.

Exclusion Criteria:

* Dementia, FTD or other neurodegenerative disorder at baseline visit
* Any psychiatric disorder that would interfere with compliance in the study.
* Use of high dose vitamin B3 supplementation within 30 days of enrollment
* Metabolic, neoplastic, or other physically or mentally debilitating disorder at baseline visit.
* Genetically confirmed mitochondrial disease
* Patients who become tracheostomized as part of the treatment of ALS
* Patients with short expected survival at the discretion of the investigator. Such cases cannot be expected to follow protocol procedures.
Comparison of High-dose IL-2 and High-dose IL-2 With Radiation Therapy in Patients With Metastatic Melanoma.

The purpose of this study is compare the response rates in patients with metastatic melanoma treated with high-dose IL-2 to patients treated with high-dose IL-2 along with radiation therapy.

All patients will receive high-dose IL-2. Half the patients enrolled will be randomly selected to receive radiation therapy to up to three tumors prior to receiving high-dose IL-2. Among the first 20 patients enrolled, those assigned to receive radiation will receive a single dose of radiation and for patients 21-44, those assigned to receive radiation will receive 2 doses of radiation.

Eligibility Criteria:
Inclusion Criteria:

* Histological confirmation of melanoma will be required by previous biopsy or cytology.
* Patients must be ≥ 18 years of age.
* Patients must have tumors amenable to SBRT in lungs, mediastinum, chest wall, bones (other than long bones), or liver (inclusive of immediately adjacent masses), 1 - 3 foci; no minimum size, but none greater than 7 cm. Patients may have other metastases but only a maximum of 3 will be treated.
* ECOG performance status of 0-1.
* Women of childbearing potential must have a serum or urine pregnancy test performed within 72 hours prior to the start of protocol treatment. The results of this test must be negative in order for the patient to be eligible. In addition, women of childbearing potential as well as male patients must agree to take appropriate precautions to avoid pregnancy.
* Patients must sign a study-specific consent form.

Exclusion Criteria:

* No metastatic site amenable to SBRT.
* Patients with brain metastases not candidates for radiosurgery.
* Previous radiation to sites proposed for radiation as part of this study.
* Patients with active systemic, pulmonary, or pericardial infection.
* Pregnant or lactating women.
* Evidence of ischemia on exercise tolerance test, stress thallium study, or baseline EKG.
* DLCO, FEV1 or FEV1/FVC less than 70% of predicted due to clinically significant underlying pulmonary disease. For any pulmonary function test values less than predicted values, the PI will review, and document the patient's suitability for high dose IL-2 therapy.
* WBC \< 3.0 x 109/L
* Hgb \< 9.0 g/dL
* AST/ALT \> 3 times the upper limit of the normal range
* total bilirubin \> 1.9 g/dL
* creatinine \> 1.9 g/dL
* Patient requires chronic steroids.